50
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this study was to clarify the significance of DNA methylation alterations during lung carcinogenesis. Infinium assay was performed using 139 paired samples of non-cancerous lung tissue (N) and tumorous tissue (T) from a learning cohort of patients with lung adenocarcinomas (LADCs). Fifty paired N and T samples from a validation cohort were also analyzed. DNA methylation alterations on 1,928 probes occurred in N samples relative to normal lung tissue from patients without primary lung tumors, and were inherited by, or strengthened in, T samples. Unsupervised hierarchical clustering using DNA methylation levels in N samples on all 26,447 probes subclustered patients into Cluster I ( n = 32), Cluster II ( n = 35) and Cluster III ( n = 72). LADCs in Cluster I developed from the inflammatory background in chronic obstructive pulmonary disease (COPD) in heavy smokers and were locally invasive. Most patients in Cluster II were non-smokers and had a favorable outcome. LADCs in Cluster III developed in light smokers were most aggressive (frequently showing lymphatic and blood vessel invasion, lymph node metastasis and an advanced pathological stage), and had a poor outcome. DNA methylation levels of hallmark genes for each cluster, such as IRX2, HOXD8, SPARCL1, RGS5 and EI24, were again correlated with clinicopathological characteristics in the validation cohort. DNA methylation profiles reflecting carcinogenetic factors such as smoking and COPD appear to be established in non-cancerous lung tissue from patients with LADCs and may determine the aggressiveness of tumors developing in individual patients, and thus patient outcome.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Lung cancer in never smokers--a different disease.

          Although most lung cancers are a result of smoking, approximately 25% of lung cancer cases worldwide are not attributable to tobacco use, accounting for over 300,000 deaths each year. Striking differences in the epidemiological, clinical and molecular characteristics of lung cancers arising in never smokers versus smokers have been identified, suggesting that they are separate entities. This Review summarizes our current knowledge of this unique and poorly understood disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chronic obstructive pulmonary disease

            Summary Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. The main cause is smoking tobacco, but other factors have been identified. Several pathobiological processes interact on a complex background of genetic determinants, lung growth, and environmental stimuli. The disease is further aggravated by exacerbations, particularly in patients with severe disease, up to 78% of which are due to bacterial infections, viral infections, or both. Comorbidities include ischaemic heart disease, diabetes, and lung cancer. Bronchodilators constitute the mainstay of treatment: β2 agonists and long-acting anticholinergic agents are frequently used (the former often with inhaled corticosteroids). Besides improving symptoms, these treatments are also thought to lead to some degree of disease modification. Future research should be directed towards the development of agents that notably affect the course of disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genome-wide DNA methylation profiling using Infinium® assay.

              Bisulfite sequence analysis of individual CpG sites within genomic DNA is a powerful approach for methylation analysis in the genome. The major limitation of bisulfite-based methods is parallelization. Both array and next-generation sequencing technology are capable of addressing this bottleneck. In this report, we describe the application of Infinium® genotyping technology to analyze bisulfite-converted DNA to simultaneously query the methylation state of over 27,000 CpG sites from promoters of consensus coding sequences (CCDS) genes. We adapted the Infinium genotyping assay to readout an array of over 27,000 pairs of CpG methylation-specific query probes complementary to bisulfite-converted DNA. Two probes were designed to each CpG site: a 'methylated' and an 'unmethylated' query probe. The probe design assumed that all underlying CpG sites were 'in phase' with the queried CpG site due to their close proximity. Bisulfite conversion was performed with a modified version of the Zymo EZ DNA Methylation™ kit. We applied this technology to measuring methylation levels across a panel of 14 different human tissues, four Coriell cell lines and six cancer cell lines. We observed that CpG sites within CpG islands (CGIs) were largely unmethylated across all tissues (~80% sites unmethylated, β < 0.2), whereas CpG sites in non-CGIs were moderately to highly methylated (only ~12% sites unmethylated, β < 0.2). Within CGIs, only approximately 3-6% of the loci were highly methylated; in contrast, outside of CGIs approximately 25-40% of loci were highly methylated. Moreover, tissue-specific methylation (variation in methylation across tissues) was much more prevalent in non-CGIs than within CGIs. Our results demonstrate a genome-wide scalable array-based methylation readout platform that is both highly reproducible and quantitative. In the near future, this platform should enable the analysis of hundreds of thousands to millions of CpG sites per sample.
                Bookmark

                Author and article information

                Journal
                Int J Cancer
                Int. J. Cancer
                ijc
                International Journal of Cancer. Journal International du Cancer
                Blackwell Publishing Ltd (Oxford, UK )
                0020-7136
                1097-0215
                15 July 2014
                19 December 2013
                : 135
                : 2
                : 319-334
                Affiliations
                [1 ]Division of Molecular Pathology, National Cancer Center Research Institute Tokyo, 104-0045, Japan
                [2 ]Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine Tokyo, 160-8582, Japan
                [3 ]Division of Genome Biology, National Cancer Center Research Institute Tokyo, 104-0045, Japan
                [4 ]Bioscience Department, Research and Development Center, Mitsui Knowledge Industry Co., Ltd. Tokyo, 105-6215, Japan
                [5 ]Division of Pathology, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital Tokyo, 104-0045, Japan
                [6 ]Division of Thoracic Surgery, Department of Thoracic Oncology, National Cancer Center Hospital Tokyo, 104-0045, Japan
                Author notes
                Correspondence to: Eri Arai, Division of Molecular Pathology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Tel.: +81-3-3542-2511, Fax: +81-3-3248-2463, E-mail: earai@ 123456ncc.go.jp

                Grant sponsor: National Cancer Center Research and Development Fund; Grant number: 23A-1 (National Cancer Center Biobank); Grant sponsor: The National Institute of Biomedical Innovation (NiBio), the Ministry of Health, Labor and Welfare of Japan, and the Japan Society for the Promotion of Science (JSPS)

                Article
                10.1002/ijc.28684
                4255314
                24921089
                ca4ed5ce-7ac4-4a43-9e3f-2ddf301303b2
                © 2013 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC

                This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 26 June 2013
                : 29 November 2013
                : 05 December 2013
                Categories
                Cancer Genetics

                Oncology & Radiotherapy
                dna methylation,infinium assay,lung adenocarcinoma,cigarette smoking,chronic obstructive pulmonary disease

                Comments

                Comment on this article